ESPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient trader: near-term edge looks unfavorable (pattern-based model points to mild downside over 1W/1M) and there\u2019s no proprietary buy signal today.", "Technicals are constructive (bullish MA stack), but momentum is fading (MACD histogram positive but contracting) and price is still below nearby resistance (~3.59).", "If you must act immediately, the higher-probability setup is to wait for either a pullback toward 3.33\u20133.08 support or a clean breakout/close above ~3.59; until then, the trade is a pass."]
["Trend: Bullish moving average alignment (SMA_5 > SMA_20 > SMA_200) suggests an underlying uptrend/basing improvement.", "Momentum: MACD histogram at 0.0353 is >0 (bullish), but \u2018positively contracting\u2019 implies upside momentum is weakening near-term.", "RSI: RSI_6 = 55.45 (neutral), indicating no immediate overbought/oversold signal.", "Key levels: Pivot 3.335 is the line-in-the-sand; Support S1 3.079 then S2 2.921. Resistance R1 3.591 then R2 3.749.", "Price context: Post-market 3.425 after -2.14% regular-session drop suggests sellers had control into the close.", "Quant pattern read-through: Similar-pattern stats imply ~60% chance of slight drift lower (next week ~-2.1%, next month ~-1.98%), which weakens the \u2018buy now\u2019 case."]
on 2026-02-25 pre-market can act as a volatility/catalyst window."]
["No fresh news catalysts in the past week to reverse the current near-term drift.", "Near-term probability tilt is modestly negative (pattern-based outlook points to small declines over 1W/1M).", "Profitability still negative (net income and EPS remain below zero), which can cap upside follow-through without new catalysts.", "Gross margin fell sharply YoY, which may raise concern about pricing/mix/cost pressures."]
["Latest quarter (2025/Q3): Revenue $87.309M, +69.10% YoY (strong top-line acceleration).", "Latest quarter (2025/Q3): Net income -$31.333M, improved +6.13% YoY (loss narrowing modestly).", "Latest quarter (2025/Q3): EPS -0.16, improved +6.67% YoY (still negative).", "Latest quarter (2025/Q3): Gross margin 52.71%, down -20.76% YoY (material deterioration despite revenue growth)."]
["Recent trend: New coverage initiation from Piper Sandler (2025-11-24/25) with an Overweight rating and a $9 price target\u2014net positive change in Street tone from this update.", "Wall Street pros: Belief in bempedoic acid franchise durability, broad label/primary prevention opportunity, evolving guidelines, and payer access supporting \u2018rapid\u2019 expansion.", "Wall Street cons (implied by fundamentals/tape): Ongoing losses and margin compression mean execution must stay strong; without near-term catalysts, the stock can chop despite bullish long-term narratives.", "Influential buyers/sellers: No recent congress trading data available; hedge funds and insiders show neutral activity trends."]
